{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Indianapolis&page=78&state=Indiana",
    "query": {
      "state": "Indiana",
      "city": "Indianapolis",
      "page": 78
    },
    "page_size": 10
  },
  "pagination": {
    "page": 78,
    "page_size": 10,
    "total_count": 8625,
    "total_pages": 863,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Indianapolis&page=79&state=Indiana&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Indianapolis&page=77&state=Indiana&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T10:01:37.827Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02723994",
      "title": "A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Asparaginase Erwinia Chrysanthemi",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pegaspargase",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Thioguanine",
          "type": "DRUG"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 171,
      "start_date": "2016-09-30",
      "completion_date": "2026-03-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-11-19T10:01:37.827Z",
      "location_count": 103,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fontana",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02723994"
    },
    {
      "nct_id": "NCT01288222",
      "title": "Selecting a Favorable KIR Donor in Unrelated HCT for AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "KIR genotype",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 506,
      "start_date": "2011-06",
      "completion_date": "2020-04",
      "has_results": false,
      "last_update_posted_date": "2021-03-11",
      "last_synced_at": "2026-11-19T10:01:37.827Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Atlanta, Georgia + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01288222"
    },
    {
      "nct_id": "NCT07223151",
      "title": "A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity, Adolescent",
        "Dietary Sugars",
        "Taste Perception",
        "Insulin Resistance",
        "Feeding Behavior"
      ],
      "interventions": [
        {
          "name": "Unsweetened Sparkling Water Replacement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Progressively Reduced Sugar Beverage Replacement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Plain Water Replacement",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Nana Gletsu Miller",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 63,
      "start_date": "2025-07-25",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-11-19T10:01:37.827Z",
      "location_count": 3,
      "location_summary": "Bloomington, Indiana • Indianapolis, Indiana • West Lafayette, Indiana",
      "locations": [
        {
          "city": "Bloomington",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "West Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07223151"
    },
    {
      "nct_id": "NCT01230853",
      "title": "A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Active Comparator: A",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator B",
          "type": "DRUG"
        },
        {
          "name": "Active Comparator B",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2010-08",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2020-11-23",
      "last_synced_at": "2026-11-19T10:01:37.827Z",
      "location_count": 8,
      "location_summary": "Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01230853"
    },
    {
      "nct_id": "NCT02619253",
      "title": "Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nabil Adra",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2016-02-23",
      "completion_date": "2023-03-28",
      "has_results": true,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-11-19T10:01:37.827Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02619253"
    },
    {
      "nct_id": "NCT01116245",
      "title": "An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Intraepithelial Neoplasia"
      ],
      "interventions": [
        {
          "name": "ADXS11-001 (Lm-LLO-E7)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Advaxis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 81,
      "start_date": "2010-04",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2016-07-27",
      "last_synced_at": "2026-11-19T10:01:37.827Z",
      "location_count": 15,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01116245"
    },
    {
      "nct_id": "NCT01139957",
      "title": "Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Carcinoma",
        "Fallopian Tube Carcinoma",
        "Ovarian Neoplasm",
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Evaluation of Cancer Risk Factors",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Study of High Risk Factors",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "30 Years and older · Female only"
      },
      "enrollment_count": 1916,
      "start_date": "2010-06-07",
      "completion_date": "2020-04-10",
      "has_results": false,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-11-19T10:01:37.827Z",
      "location_count": 141,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 106 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01139957"
    },
    {
      "nct_id": "NCT03446001",
      "title": "Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "TRx0237 16 mg/day",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "DRUG"
        },
        {
          "name": "TRx0237 8 mg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TauRx Therapeutics Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "Up to 90 Years"
      },
      "enrollment_count": 598,
      "start_date": "2017-12-01",
      "completion_date": "2023-04-04",
      "has_results": true,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-11-19T10:01:37.827Z",
      "location_count": 60,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 44 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03446001"
    },
    {
      "nct_id": "NCT01473602",
      "title": "Second Study of the Effect of Teriparatide on Hip Fracture Healing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Femur Neck Fracture"
      ],
      "interventions": [
        {
          "name": "Teriparatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Calcium supplementation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Vitamin D supplementation",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2012-01",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-04-16",
      "last_synced_at": "2026-11-19T10:01:37.827Z",
      "location_count": 19,
      "location_summary": "San Diego, California • Golden, Colorado • Washington D.C., District of Columbia + 16 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Morton Grove",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01473602"
    },
    {
      "nct_id": "NCT01730937",
      "title": "Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Recurrent Adult Primary Liver Cancer"
      ],
      "interventions": [
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "stereotactic body radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 193,
      "start_date": "2013-04",
      "completion_date": "2025-09-04",
      "has_results": true,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-11-19T10:01:37.827Z",
      "location_count": 41,
      "location_summary": "Berkeley, California • Los Angeles, California • San Francisco, California + 32 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01730937"
    }
  ]
}